Single Domain Biotherapeutics

Single Domain Biotherapeutics

Welcome to

Isogenica

Excellence in Single Domain Biotherapeutics

Isogenica develops therapeutic VHH:
highly versatile small format antibodies which we use to construct next generation biotherapeutics for the treatment of cancer, inflammation and other serious diseases.

Our VHH can be assembled to create bi-specific and multi-specific biotherapeutics, or used to achieve targeted drug delivery as components of ADCs and cell and gene therapies including CAR-Ts.

News & Events

🎂 Join us in celebrating our 25th birthday

🎂 Join us in celebrating our 25th birthday

Not many Biotechs get to turn 25, but this month at Isogenica we are celebrating our quarter century! This edition we look back through our 25 years of new technologies, acknowledging our wonderful partnerships….

Isogenica’s partnerships with global biopharmaceutical companies have resulted in a deep pipeline including one clinical Phase II asset and eleven partnered pre-clinical and discovery programs.

Isogenica works with partners through collaborative research and commercial licenses to further develop proprietary LlamdA® VHH or to discover novel LlamdA® VHH as direct therapeutics and targeting agents.

Partnerships

Isogenica Biopharmaceutical Partnerships

Careers at Isogenica

A career at Isogenica provides an opportunity to lead, execute or support the commercial development of next generation biotherapeutics.